Arcus Biosciences, Inc. (RCUS)
| Market Cap | 3.80B +236.8% |
| Revenue (ttm) | 117.00M -55.3% |
| Net Income | -460.00M |
| EPS | -3.86 |
| Shares Out | 127.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,606 |
| Open | 29.92 |
| Previous Close | 29.85 |
| Day's Range | 29.20 - 29.93 |
| 52-Week Range | 10.55 - 31.74 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 38.33 (+28.58%) |
| Earnings Date | Aug 5, 2026 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in... [Read more]
Financial Performance
In 2025, Arcus Biosciences's revenue was $247.00 million, a decrease of -4.26% compared to the previous year's $258.00 million. Losses were -$353.00 million, 24.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price target is $38.33, which is an increase of 28.58% from the latest price.
News
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences price target raised to $23 from $22 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arcus Biosciences (RCUS) to $23 from $22 and keeps an Equal Weight rating on the shares.
Arcus Biosciences price target raised to $42 from $34 at Goldman Sachs
Goldman Sachs analyst Richard Law raised the firm’s price target on Arcus Biosciences (RCUS) to $42 from $34 and keeps a Buy rating on the shares.
Arcus Biosciences price target raised to $43 from $41 at Wedbush
Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $43 from $41 and keeps an Outperform rating on the shares following quarterly results and corporate updates. The firm…
Arcus Biosciences price target raised to $26 from $23 at Wells Fargo
Wells Fargo raised the firm’s price target on Arcus Biosciences (RCUS) to $26 from $23 and keeps an Equal Weight rating on the shares. While the October update should provide…
Arcus Biosciences reports Q2 EPS (72c), consensus (81c)
Reports Q2 revenue $41M, consensus $21.98M. “Our recent publication in Nature demonstrated our commitment to being the scientific leader in HIF-2alpha biology and translational medicine. We are levera...
Arcus Biosciences Earnings Call Transcript: Q2 2026
Strong progress in oncology and immunology pipelines, with casdatifan advancing as a potential backbone therapy for RCC and multiple new collaborations expanding its reach. Financials remain robust with $775M in cash, and key data readouts are expected in October and 2027.
Arcus Biosciences Earnings release: Q2 2026
Arcus Biosciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Arcus Biosciences Quarterly report: Q2 2026
Arcus Biosciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Arcus Biosciences Slides: Q2 2026
Arcus Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Arcus Biosciences price target raised to $29 from $25 at BofA
BofA raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps a Neutral rating on the shares. While early data support casdatifan’s best-in-class potential, it…
Arcus, Summit enter into clinical trial collaboration over kidney cancer
Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT) announced a clinical trial collaboration to evaluate the safety and efficacy of Arcus’s casdatifan, an investigational hypoxia-inducible factor ...
Arcus Biosciences announces clinical supply pact with AVEO Oncology
Arcus Biosciences (RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company. Under the agreement, the companies will evaluate casdatifan, Arcus’s investigational small-molecu...
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therap...
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinat...
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
Arcus Biosciences price target raised to $45 from $32 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Arcus Biosciences (RCUS) to $45 from $32 and keeps a Buy rating on the shares. The firm says casdatifan…
Arcus Biosciences announces publication on ARC-20 study research
Arcus Biosciences (RCUS) announced a publication in Nature describing new research from the ARC-20 study. The publication evaluated casdatifan, an investigational, small-molecule HIF-2a inhibitor, as ...
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus Biosciences Transcript: AGM 2026
The meeting confirmed quorum and addressed three proposals: director elections, auditor ratification, and executive compensation, all of which passed. No questions were raised, and final voting results will be published in a Form 8-K.
Arcus Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Casdatifan is positioned as a potential backbone therapy for RCC, with multiple studies across all lines of treatment and significant upcoming data readouts. The company maintains strong financials, robust I&I pipeline, and a strategy to retain full commercial rights while leveraging clinical collaborations.
Arcus Biosciences Slides: FY 2026
Arcus Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 9, 2026.